Replies to post #125141 on Cytodyn Inc (CYDY)

[eklab]

Kook, very disappointing in your thinking and write-up of Leronlimab.

If you would have been here end of 2019 to February 2020, you would have known, that Leronlimab was ready, very effective, very little side effects, ready to help serious ill persons in an instant, compared with what other drugs were doing.

Don`t be alarmed, you are not the only one with that funny idea, that Leronlimab was not perfected and needed improving.

When Nader P. trusted the FDA and turned his best of the best pharmaceutical product over to the FDA, they first approved it after examined it, but when they realized how efficient it was as a great competitor to all other existing products, they shelved it with all kind of excuses for not approving it.

[PSea]

Uplisting is critical to raising money at reasonable rates. It's also critical to institutional investment in the stock.

We'll have to agree to disagree. The two of you are in the minority. Anyone and everyone that can, will choose to uplist. Especially pre-revenue companies.